首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1622084

癌症治療藥市場:癌症類型，療法，終端用戶，各地區，2024年～2031年

Cancer Therapeutics Market By Cancer Type, Therapy, End Users, & Region for 2024-2031

出版日期: 2024年09月21日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

癌症藥物市場評估，2024-2031

癌症治療市場已達到一個重要里程碑，到 2023 年將達到 1,499.2 億美元。這項成就的實現有多種因素，包括加強研發力度、加強製藥公司之間的合作以及加強對醫療保健領域的投資。預計2024年至2031年期間，該市場將經歷一個充滿希望的發展軌跡，複合年增長率預計為14.6%。預計到 2031 年將飆升至驚人的 4,914.1 億美元，反映了該行業內的持續成長勢頭和不斷變化的動態。

這一增長得益於全球癌症發病率上升、政府促進早期檢測的努力、癌症研究的穩步增長以及技術進步等因素，所有這些我們都為治療藥物的進步做出了貢獻。

癌症藥物市場定義/概述

癌症藥物包括針對癌細胞變化以抑制腫瘤生長的治療方法，例如放射療法、化學療法和手術。這些治療的應用根據癌症的類型和階段而有所不同，並且正在進行研究和臨床試驗來探索免疫治療、標靶治療、荷爾蒙治療和幹細胞移植等治療方法。市場區隔是根據癌症類型和最終用戶進行的，市場受到全球癌症發病率上升的推動，預計到 2031 年，癌症發病率將翻一番，尤其是在亞洲、歐洲和美洲。

製藥公司之間不斷加強的合作和研究工作進一步推動了市場成長。市場擴張是由政府提高癌症意識和個人化醫療需求的措施所推動的。

推動癌症治療藥物市場成長的因素有哪些？

全球癌症盛行率不斷上升，特別是在亞洲、歐洲和美洲等地區，推動了對有效治療方案的需求。癌症患者數量的增加需要先進的治療藥物，促使市場擴張。癌症治療的創新很大程度上是由腫瘤學領域的研究和開發的增加所推動的。透過研究和臨床試驗不斷探索推動新藥和治療方法的發現，從而以更有效的解決方案豐富市場。

此外，製藥公司、研究機構和各個利害關係人之間的合作也促進了創新和癌症藥物開發的加速。這種夥伴關係有利於資源匯集和知識共享，從而加強管道並更快地將新藥推向市場。此外，政府旨在提高癌症意識、促進早期檢測和提供研究資金的措施也促進了市場成長。

癌症患者可用的治療選擇的擴大是由基因組測試和技術創新的進步推動的，也是由針對每個患者的情況量身定制的個性化醫療不斷增長的需求推動的。這些因素的匯合，為抗癌藥物市場的持續發展和擴大創造了良好的環境。

哪些因素導致癌症治療藥物市場銷售大幅下滑？

由於重磅藥物的專利到期而導致仿製藥的出現增加了競爭並降低了品牌抗癌藥物的價格。競爭的加劇給製藥公司帶來了挑戰，並導致企業利潤下降。此外，新抗癌藥物的取得受到藥物審批和報銷的嚴格監管要求以及醫療保健支付者的定價壓力的限制。監管審批的延遲和報銷政策的變化可能會進一步限制抗癌藥物的採用並對銷售產生負面影響。

品牌抗癌藥物（尤其是專利保護已過期的藥物）引進仿製藥，導致原廠藥公司的價格和銷售大幅下降。治療範式也受到癌症研究進展以及醫療保健提供者對免疫療法和標靶療法等新療法偏好變化的影響。這種轉變可能會減少傳統化療的使用，並進一步影響傳統抗癌藥物的銷售。經濟衰退、醫療保健支出變化、報銷波動等經濟因素，以及治療依從性和可及性方面的挑戰，使製藥公司在這種競爭格局中維持收入成長所面臨的挑戰更加複雜。

Significant milestones were achieved in the Cancer Therapeutics Market, with a value of USD 149.92 Billion attained in 2023. Various factors, including heightened research and development endeavors, greater collaboration among pharmaceutical entities, and amplified investments within the healthcare sector, fueled this achievement. The market is anticipated to witness a promising trajectory, with a projected CAGR of 14.6% during the forecast period from 2024 to 2031. By 2031, it is expected to soar to an impressive value of USD 491.41 Billion, reflecting the sustained momentum and evolving dynamics within the industry.

This growth is underpinned by factors such as the escalating prevalence of cancer globally, governmental initiatives promoting early detection, and the steady rise in cancer research endeavors, coupled with technological advancements, all contributing to the advancement of cancer therapeutics.

Cancer Therapeutics Market: Definition/Overview

Cancer therapeutics encompass treatments aimed at targeting alterations in cancer cells to impede tumor growth, including radiotherapy, chemotherapy, and surgery. The application of these therapies varies based on cancer type and stage, with ongoing research and clinical trials exploring treatments such as immunotherapy, targeted therapy, hormone therapy, and stem cell transplant. Market segmentation, based on cancer type and end users, is driven by the global rise in cancer prevalence, expected to double by 2031, particularly in Asia, Europe, and the Americas.

Market growth is further propelled by collaboration between pharmaceutical companies and increased research efforts. Market expansion is driven by government initiatives for cancer awareness and the demand for personalized medicine.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What Factors are Driving the Growth of the Cancer Therapeutics Market?

The demand for effective treatment options is propelled by the escalating prevalence of cancer globally, particularly in regions such as Asia, Europe, and the Americas. This rise in cancer cases necessitates advanced therapeutics, leading to market expansion. Innovation in cancer therapeutics is significantly contributed by heightened research and development endeavors within the field of oncology. Continuous exploration through studies and clinical trials facilitates the discovery of novel drugs and treatment modalities, thereby enriching the market with more effective solutions.

Moreover, innovation and the acceleration of cancer therapeutics development are fostered by collaborative efforts among pharmaceutical companies, research institutions, and various stakeholders. These partnerships facilitate resource pooling and knowledge sharing, resulting in more robust pipelines and the quicker introduction of new drugs to the market. Furthermore, market growth is bolstered by government initiatives aimed at raising cancer awareness, promoting early detection, and providing funding for research.

The expansion of treatment options available to cancer patients is driven by the growing demand for personalized medicine tailored to individual patient profiles, fueled by advances in genomic testing and technological innovations. This convergence of factors creates a favorable environment for the continuous progression and expansion of the Cancer Therapeutics Market.

What Factors are Plummeting Sales of Cancer Therapeutics Market?

The availability of generic versions due to patent expirations on blockbuster drugs intensifies competition and drives down prices for branded cancer therapeutics. This increased competition poses challenges for pharmaceutical companies, leading to reduced sales revenue. Also, easy accessibility to new cancer therapeutics is restricted by stringent regulatory requirements for drug approval and reimbursement, as well as pricing pressures from healthcare payers. Delays in regulatory approvals or changes in reimbursement policies further limit the adoption of cancer therapeutics, resulting in negative impact on sales.

The introduction of generic versions of branded cancer therapeutics, particularly for drugs losing patent protection, contributes to significant price erosion and decreased sales for originator companies. Treatment paradigms are also influenced by advances in cancer research, and shifting preferences of healthcare providers towards emerging therapies such as immunotherapy and targeted treatments. This shift may reduce the utilization of traditional chemotherapy, further impacting sales of conventional cancer therapeutics. Economic factors, including downturns, changes in healthcare spending, and fluctuations in reimbursement, as well as challenges related to treatment adherence and access issues, further compound the challenges faced by pharmaceutical companies in maintaining revenue growth in this competitive landscape.

Category-Wise Acumens

Which Therapy Type Category Holds the Dominant Market Share in the Cancer Therapeutics Market?

In the forecasted period, the targeted therapy segment is expected to demonstrate the highest Compound Annual Growth Rate (CAGR), attributed to its specificity toward cancer cells while minimizing toxicity to off-target cells. This category encompasses various therapeutic approaches, such as hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules.

With cancer cells precisely targeted and healthy cells spared from harm, targeted therapy presents a promising avenue for more effective and tolerable cancer treatment options. Consequently, it contributes significantly to its dominance in the Cancer Therapeutics Market.

Will the Emergence of Cancer and Radiation Therapy Centres Drive Growth in the Cancer Therapeutics Market?

The growth of the Cancer Therapeutics Market is expected to be driven by the emergence of Cancer and Radiation Therapy Centres. It is anticipated that the largest market share will be held by the Cancer & Radiation Therapy Centre due to several factors. These centers are regarded as pivotal in the administration of cancer therapeutics, serving as hubs for a significant number of cancer treatments. Patients are often provided with a variety of treatments, including chemotherapy, radiotherapy, and targeted therapy, all of which contribute to the demand for cancer therapeutics.

Additionally, specialized equipment and expertise required for advanced treatment modalities are often housed within these centers, further driving the need for therapeutic interventions. Therefore, as Cancer and Radiation Therapy Centres continue to expand and cater to the increasing number of cancer patients, they are poised to play a central role in fueling the growth of the Cancer Therapeutics Market.

Could North America Drive an Increase in the Sales within the Cancer Therapeutics Market?

An increase in sales within the Cancer Therapeutics Market could be driven by North America. The region is positioned to dominate the market, primarily due to the widespread adoption of cancer therapeutics and significant funding provided by various organizations operating within the region. With advanced cancer treatment options being widely adopted and substantial financial support being provided by both public and private sectors in North America, the region is poised to stimulate growth in sales within the Cancer Therapeutics Market.

Furthermore, North America's leadership in the adoption of advanced cancer treatment options and its robust financial support from both public and private sectors contribute to its advantageous position. This favorable environment fosters a conducive landscape for the expansion of cancer therapeutics sales, positioning North America as a key driver of market growth.

Will the Sales of Cancer Therapeutics Market fare well in Asia Pacific?

The sales of the Cancer Therapeutics Market are expected to perform well in the Asia Pacific region. With high prevalence of cancer and increasing awareness about the importance of early detection and treatment, there is a significant growth in demand for cancer therapeutics in Asia Pacific. The region's potential for robust sales of cancer therapeutics is further enhanced by advancements in healthcare infrastructure and increasing investments in research and development activities. A surge in collaborations between pharmaceutical companies and healthcare institutions is being witnessed in this region, fostering innovation and the introduction of novel cancer treatment options, driving market growth.

The Government initiatives aimed at improving cancer care and access to treatment, along with the growing adoption of personalized medicine approaches, are expected to bolster the sales of cancer therapeutics in Asia Pacific. As healthcare systems in countries across the Asia Pacific continue to evolve and improve, there is a growing focus on addressing the unmet medical needs of cancer patients, presenting significant opportunities for market expansion in the region.

Competitive Landscape

Examining the competitive landscape of the Cancer Therapeutics Market is considered crucial for gaining insights into the industry's dynamics. This research aims to analyze the competitive landscape, focusing on key players, market trends, innovations, and strategies. By conducting this analysis, valuable insights will be provided to industry stakeholders, assisting them in effectively navigating the competitive environment and seizing emerging opportunities. Understanding the competitive landscape will enable stakeholders to make informed decisions, adapt to market trends, and develop strategies to enhance their market position and competitiveness in the Cancer Therapeutics Market.

Some of the prominent players operating in the Cancer Therapeutics Market include:

Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, Astellas Pharma Inc., Pfizer Inc., Novartis AG, Merck KGaA, Bayer AG, and Takeda Pharmaceutical Company Limited.

Latest Developments

In February 2024, Bristol-Myers Squibb attained FDA approval for OPDIVO (nivolumab) alongside Yervoy (ipilimumab) for the initial treatment of patients diagnosed with locally advanced or metastatic urothelial carcinoma (bladder cancer).

In February 2024, Merck & Co. revealed encouraging outcomes from a Phase 3 clinical trial of Keytruda (pembrolizumab) combined with chemotherapy as the primary therapy for advanced non-small cell lung cancer (NSCLC). The study exhibited a statistically significant enhancement in overall survival in comparison to chemotherapy alone.

In January 2024, Johnson & Johnson's Janssen unit disclosed favorable findings from a Phase 3 trial of Darzalex (daratumumab) combined with bortezomib and lenalidomide for managing patients with newly diagnosed multiple myeloma. The study highlighted a statistically significant advancement in progression-free survival when contrasted with the administration of lenalidomide and bortezomib alone.

1. INTRODUCTION OF GLOBAL CANCER THERAPEUTICS MARKET

1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources

4. GLOBAL CANCER THERAPEUTICS MARKET OUTLOOK

4.1. Overview
4.2. Market Dynamics
- 4.2.1. Drivers
- 4.2.2. Restraints
- 4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis

5. GLOBAL CANCER THERAPEUTICS MARKET, BY CANCER TYPE

5.1. Overview
5.2. Blood Cancer
5.3. Lung Cancer
5.4. Breast Cancer
5.5. Gastrointestinal Cancer
5.6. Colorectal Cancer
5.7. Gynecologic Cancer
5.8. Prostate Cancer
5.9. Others

6. GLOBAL CANCER THERAPEUTICS MARKET, BY THERAPY

6.1. Overview
6.2. Chemotherapy
6.3. Targeted Therapy
6.4. Immunotherapy
6.5. Hormonal Therapy
6.6. Others

7. GLOBAL CANCER THERAPEUTICS MARKET, BY END USERS

7.1. Overview
7.2. Hospitals
7.3. Specialty Clinics
7.4. Cancer and Radiation Therapy Centres

8. GLOBAL CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

8.1. Overview
8.2. North America
- 8.2.1. U.S.
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. Europe
- 8.3.1. Germany
- 8.3.2. U.K.
- 8.3.3. France
- 8.3.4. Rest of Europe
8.4. Asia Pacific
- 8.4.1. China
- 8.4.2. Japan
- 8.4.3. India
- 8.4.4. Rest of Asia Pacific
8.5. Rest of the World
- 8.5.1. Latin America
- 8.5.2. Middle East & Africa

9. GLOBAL CANCER THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

9.1. Overview
9.2. Company Market Ranking
9.3. Key Development Strategies

10. COMPANY PROFILES

10.1. F. Hoffmann-La Roche AG
- 10.1.1. Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Outlook
- 10.1.4. Key Developments
10.2. Bristol-Myers Squibb Company
- 10.2.1. Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Outlook
- 10.2.4. Key Developments
10.3. AbbVie, Inc.
- 10.3.1. Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Outlook
- 10.3.4. Key Developments
10.4. Johnson & Johnson
- 10.4.1. Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Outlook
- 10.4.4. Key Developments
10.5. Celgene Corporation
- 10.5.1. Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Outlook
- 10.5.4. Key Developments
10.6. Astellas Pharma Inc.
- 10.6.1. Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Outlook
- 10.6.4. Key Developments
10.7. Pfizer, Inc.
- 10.7.1. Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Outlook
- 10.7.4. Key Developments
10.8. Novartis AG
- 10.8.1. Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Outlook
- 10.8.4. Key Developments
10.9. Merck KGaA
- 10.9.1. Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Outlook
- 10.9.4. Key Developments
10.10. Bayer AG
- 10.10.1. Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Outlook
- 10.10.4. Key Developments